Zentalis Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 294.00 thousand shares for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2024-05-07
- Zentalis Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2024-03-31 was 294.00K shares.
- Zentalis Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2023-03-31 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month |
|---|---|
| 2024-03-31 | 294.00K shares 10-Q · filed 2024-05-07 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |